|
Title
|
|
|
|
Survival outcomes according to TIMP1 and EGFR expression in heavily treated patients with advanced non-small cell lung cancer who received biweekly irinotecan plus bevacizumab
| |
|
Author
|
|
|
|
| |
|
Institution/Organisation
|
|
|
|
Latin-Amer Consortium Invest Lung
| |
|
Abstract
|
|
|
|
| Background: Heavily treated patients with non-small cell lung cancer (NSCLC) have few treatment options, while irinotecan and bevacizumab have proven synergistic action in preclinical studies. Patients and Methods: A total of 49 patients with heavily treated NSCLC were enrolled from 2011-2014 and treated with irinotecan and bevacizumab. Treatment response along with mutational status of epidermal growth factor receptor (EGFR), and tissue inhibitor of metalloproteinases-1 (TIMP1) and EGFR expression were evaluated. Progression-free (PFS) and overall (OS) survival were monitored. Results: Median follow-up was 13.2 months. Twenty-three patients had received three or more prior therapy lines. Overall response rate was 32% [95% confidence interval (CI)=22%-39%] and 26% of patients achieved stable disease. Median PFS was 4.4 (95% CI=2.8-8.3) months and median OS 18.0 (95% CI=16.2-30.7) months. Nine patients harboring EGFR mutations had a long-lasting partial response. A shorter OS was found in patients with a higher TIMP1 expression (p=0.006). Conclusion: Irinotecan combined with bevacizumab had favorable antitumor activity in heavily pretreated patients with NSCLC. These results suggest this is a reasonable strategy, particularly for patients with low TIMP1 expression. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Anticancer research. - Athens
| |
|
Publication
|
|
|
|
Athens
:
2017
| |
|
ISSN
|
|
|
|
0250-7005
| |
|
DOI
|
|
|
|
10.21873/ANTICANRES.12097
| |
|
Volume/pages
|
|
|
|
37
:11
(2017)
, p. 6429-6436
| |
|
ISI
|
|
|
|
000416143900061
| |
|
Pubmed ID
|
|
|
|
29061829
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|